A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Fisher Builds Stake And SHASTA Readouts Approach

Simply Wall St.03-19

Arrowhead Pharmaceuticals (ARWR) is back in focus after Ken Fisher’s fund increased its holdings and management spotlighted upcoming Phase III SHASTA-3 and SHASTA-4 readouts for plozasiran, which has ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620144932?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-19 14:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620144932","market":"hk","top_or_hot":-1,"title":"A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Fisher Builds Stake And SHASTA Readouts Approach","media":"Simply Wall St.","content":"<div>\n<p>Arrowhead Pharmaceuticals (ARWR) is back in focus after Ken Fisher’s fund increased its holdings and management spotlighted upcoming Phase III SHASTA-3 and SHASTA-4 readouts for plozasiran, which has ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-as-fisher\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Fisher Builds Stake And SHASTA Readouts Approach</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Fisher Builds Stake And SHASTA Readouts Approach\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-19 14:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-as-fisher><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arrowhead Pharmaceuticals (ARWR) is back in focus after Ken Fisher’s fund increased its holdings and management spotlighted upcoming Phase III SHASTA-3 and SHASTA-4 readouts for plozasiran, which has ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-as-fisher\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-as-fisher","article_id":"2620144932","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-as-fisher","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620144932","pubTimestamp":1773900815,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Arrowhead Pharmaceuticals (ARWR) is back in focus after Ken Fisher’s fund increased its holdings and management spotlighted upcoming Phase III SHASTA-3 and SHASTA-4 readouts for plozasiran, which has been flagged as a multibillion dollar commercial opportunity.\nSee our latest analysis for Arrowhead Pharmaceuticals.\nAt a share price of US$56.71, Arrowhead has had a 1 month share price return of 11.14% and a year to date share price decline of 16.34%, set against a very large 1 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","ARWR":"Arrowhead Research Corporation","BK4139":"生物科技","BK4588":"碎股"},"translate_title":"随着费舍尔增持股份和沙斯塔读数方法，看看Arrowhead Pharmaceuticals(ARWR)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1.5},"content_text":"Arrowhead Pharmaceuticals (ARWR) is back in focus after Ken Fisher’s fund increased its holdings and management spotlighted upcoming Phase III SHASTA-3 and SHASTA-4 readouts for plozasiran, which has been flagged as a multibillion dollar commercial opportunity. See our latest analysis for Arrowhead Pharmaceuticals. At a share price of US$56.71, Arrowhead has had a 1 month share price return of 11.14% and a year to date share price decline of 16.34%, set against a very large 1 year total shareholder return of about 3.7x. This suggests that long term momentum contrasts with more cautious recent sentiment as investors weigh Fisher’s increased stake and the upcoming SHASTA-3 and SHASTA-4 readouts. If you are looking for other high potential biotech names tied to similar themes, it could be worth scanning for RNA focused healthcare names using our 35 healthcare AI stocks With Arrowhead trading at US$56.71, an indicated intrinsic value gap of about 61% and a roughly 43% discount to analyst targets raise a key question: is this genuine mispricing, or is the market already factoring in future growth? AdvertisementMost Popular Narrative: 11.5% Undervalued With Arrowhead closing at $56.71 against a most followed fair value estimate of $64.08, the current price sits below that narrative benchmark and puts extra focus on what is being assumed about revenue, margins and risk.  Arrowhead's advancing late-stage clinical pipeline, especially the expected launch of plozasiran for FCS and SHTG, plus pivotal studies for three other RNAi therapies targeting major unmet needs, positions the company to capitalize on rising demand for treatments driven by an aging population and increasing prevalence of chronic and genetic diseases, which could significantly accelerate revenue growth as approvals and launches materialize.  Read the complete narrative. Curious what kind of revenue path and margin profile sit behind that fair value, and how a very high future earnings multiple is being justified? The narrative leans heavily on a detailed set of assumptions around pipeline timing, partnership economics and long term profitability that go well beyond a simple P/E snapshot. Result: Fair Value of $64.08 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on milestones converting as planned and SHASTA readouts landing cleanly, since partner delays or weaker data could quickly undercut that undervalued narrative. Find out about the key risks to this Arrowhead Pharmaceuticals narrative. Another View On Valuation While the narrative fair value points to Arrowhead being undervalued, the current P/E of 39.3x is roughly double both the US Biotechs industry at 20x and the peer average of 19.4x, and also well above a fair ratio of 19.9x. This suggests meaningful valuation risk if sentiment cools. That kind of premium multiple can persist for a time. However, it also raises the question of how much future success is already embedded in the price and how much room is left if expectations slip even slightly, or if peers start to close the gap. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ARWR P/E Ratio as at Mar 2026Next Steps Given all this mixed sentiment around price, growth expectations and risk, it makes sense to move quickly and review the numbers yourself. To understand what is driving optimism, take a closer look at the 2 key rewards Looking for more investment ideas? If Arrowhead has your attention, do not stop here. Use the tools available to quickly surface other opportunities that could fit your goals and risk tolerance.  Target potential value opportunities by scanning companies that appear mispriced on quality and fundamentals with the 49 high quality undervalued stocks. Prioritize resilience by focusing on businesses that score well on financial strength using the solid balance sheet and fundamentals stocks screener (40 results). Hunt for lesser known prospects with solid fundamentals by checking the screener containing 26 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620144932","isCrawlerRequest":true}